Pages that link to "Q48361872"
Jump to navigation
Jump to search
The following pages link to The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia (Q48361872):
Displaying 50 items.
- Clozapine versus typical neuroleptic medication for schizophrenia (Q24240931) (← links)
- Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes (Q24655969) (← links)
- Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol (Q28362116) (← links)
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. (Q30457800) (← links)
- Histamine H1 receptor involvement in prepulse inhibition and memory function: relevance for the antipsychotic actions of clozapine (Q30488886) (← links)
- Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice (Q30493115) (← links)
- Neuroimaging of cognitive disability in schizophrenia: search for a pathophysiological mechanism (Q31120601) (← links)
- Elevated GRIA1 mRNA expression in Layer II/III and V pyramidal cells of the DLPFC in schizophrenia. (Q33302991) (← links)
- Measuring neuropsychological change in schizophrenia with novel antipsychotic medications (Q33877837) (← links)
- Treating cognitive dysfunction in patients with schizophrenia (Q33877844) (← links)
- Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study (Q34201647) (← links)
- Neuropsychological change in schizophrenia after 6 weeks of clozapine (Q34201654) (← links)
- Cognition in schizophrenia: Past, present, and future (Q34224025) (← links)
- Neurological soft signs, cognitive dysfunction and ventricular brain ration in schizophrenics. (Q34250004) (← links)
- Drug safety and efficacy evaluation of sertindole for schizophrenia (Q34300628) (← links)
- Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia (Q34313688) (← links)
- Epigenetic signaling in schizophrenia (Q34482708) (← links)
- Cognitive effects and antipsychotic treatment. (Q35035137) (← links)
- Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the Paired Associate Recognition Test (Q35095245) (← links)
- Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment (Q35102457) (← links)
- Evidence-based treatment for schizophrenia (Q35623212) (← links)
- Predictors and markers of clozapine response (Q36045493) (← links)
- First- and second-generation antipsychotic medication and cognitive processing in schizophrenia (Q36228233) (← links)
- Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments (Q36307544) (← links)
- Symptom domains of schizophrenia: the role of atypical antipsychotic agents (Q36626242) (← links)
- Psychomotor slowing in schizophrenia (Q36648517) (← links)
- Methods for treating cognitive deficits in schizophrenia (Q36752922) (← links)
- Executive function in schizophrenia: what impact do antipsychotics have? (Q36853717) (← links)
- Neurocognitive costs and benefits of psychotropic medications in older adults (Q37001163) (← links)
- The cognitive neuroscience of memory function and dysfunction in schizophrenia (Q37169856) (← links)
- Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function (Q37338702) (← links)
- Cognitive factors for predicting treatment response in schizophrenic patients: one-year follow-up study (Q37483935) (← links)
- Discriminant cognitive factors in responder and non-responder patients with schizophrenia (Q38446439) (← links)
- Memory impairment in schizophrenia--a comparison with that observed in the Alcoholic Korsakoff syndrome. (Q38467304) (← links)
- The neuropsychology of schizophrenia: relations with clinical and neurobiological dimensions (Q40370817) (← links)
- Prospects for pharmacotherapy of schizophrenia (Q40401417) (← links)
- Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground (Q40424300) (← links)
- Cognitive deficits in schizophrenia. (Q40825764) (← links)
- Cognitive function in schizophrenia--do neuroleptics make a difference? (Q40899271) (← links)
- Neurocognitive impairment in schizophrenia and how it affects treatment options (Q40899543) (← links)
- Mechanisms of action of atypical antipsychotic drugs: a critical analysis (Q41232968) (← links)
- Schizophrenia and antipsychotic somatic treatment (Q41459295) (← links)
- Neuropsychological evidence for frontostriatal dysfunction in schizophrenia (Q41652458) (← links)
- HDAC2 as a new target to improve schizophrenia treatment (Q41989010) (← links)
- Emerging role of sertindole in the management of schizophrenia (Q42427678) (← links)
- Interconnected parallel circuits between rat nucleus accumbens and thalamus revealed by retrograde transynaptic transport of pseudorabies virus. (Q42435044) (← links)
- PPI deficit induced by amphetamine is attenuated by the histamine H1 antagonist pyrilamine, but is exacerbated by the serotonin 5-HT2 antagonist ketanserin (Q42919813) (← links)
- Phencyclidine withdrawal disrupts episodic-like memory in rats: reversal by donepezil but not clozapine. (Q43126180) (← links)
- Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment (Q43621463) (← links)
- Cognitive dysfunction in schizophrenia. (Q43813326) (← links)